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ABSTRACT 
This research aimed to amplify a 1700 bp fragment of rpoB gene of multidrug resistance M. 
tuberculosis (MDR-TB) isolate and determine types of mutation beyond the core region (hot-spot region). 
DNA sequencing studies indicate that more than 95% of rifampin-resistant M. tuberculosis strains have 
mutations within the 81-bp hot-spot region (codons 507 to 533) of the RNA polymerase β-subunit (rpoB). 
Since almost 90 % of rifampicin resistant isolate are also resistant to isoniazid, mutation in rpoB gene 
become important as a surrogate marker for MDR-TB. MDR- TB isolates used  for this research, namely 
isolate 885, was collected by Regional Health Laboratory of Surabaya. PCR was used to amplify the gene, on 
described steps : a cycle of preheating at 95°C for 15 minutes, amplifying in 45 cycles ( 1 minute at 94°C, 1 
minute at 58°C,  1 minute 72°C) and post extension for 5 minutes at 72°C. The mutations were detected by 
sequencing and alignment using MEGA4. The result of this research showed that there were new mutations 
downstream of the core region of rpoB.  Sequence analysis showed  some mutations such as S594A, S626V, 
T629A. In conclusion, it is reported  for the first time, new mutations at downstream region of the core 
region of rpoB. 
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INTRODUCTION 
Tuberculosis is a major cause of death among 
people all around the world. Indonesia ranks third on 
the list of 22 high-burden tuberculosis (TB) countries 
in the world. According to the World Health 
Organization’s (WHO’s) Global Tuberculosis Control 
Report 2008, there was an estimated 535,000 new TB 
cases and an estimated incidence rate of 105 new 
sputum smear-positive (SS+) cases per 100,000 people 
in 2006. Based on WHO disability-adjusted life-year 
calculations, TB is responsible for 6.3 percent of the 
total disease burden in Indonesia, compared with 3.2 
percent in the Southeast Asian region.
1
 
Eventhough,  regiment of four drug combination 
has been implemented, single-drug resistant  and 
multi-drug resistant of Mycobacterium tuberculosis 
(MDR-TB) are continuously increasing.  A major 
challenge to TB control in Indonesia is the 
containment of multidrug- resistant (MDR) TB. Though 
the MDR rate is still relatively low, the total number of 
MDR cases is considerable due to the large numbers of 
TB patients. It is estimated that yearly there are at 
least between 5,000 and 10,000 new SS+ MDR-TB 
patients. MDR-TB is generated mainly due to the large 
numbers of TB patients who are inadequately treated. 
The private sector also provides TB treatment but the 
treatment outcomes are not captured by the National 
TB Control Program (NTCP) surveillance system. Based 
on the WHO 2008 report, MDR-TB rates among 
previously treated cases is 19 percent. The high 
defaulter rate and the misuse of second-line drugs in 
hospitals are contributing to the increase of drug-
resistant TB. The first representative drug resistance 
survey in Java is currently being completed, with 
support from USAID. Ninety-eight percent of 1,226 
samples have been tested for drug resistance. 
Preliminary results of this survey indicate that the 
level of MDR-TB is around 1.5 percent among new 
patients and 14 percent among re-treatment cases.
1 
According to the World Health Organization 
(WHO), MDR-TB is a form of TB that does not respond 
to the standard six month treatment using first line-
drugs (i.e. at least resistant to isoniazid and 
rifampicin). Rifampin resistance is of particular 
epidemiologic importance, since it represents a 
valuable surrogate marker for multidrug-resistant 
(MDR) tuberculosis strains, and the prevalence of 
MDR strains is a significant obstacle to tuberculosis 
therapy. DNA sequencing studies indicate that more 
than 95% of rifampin-resistant M. tuberculosis strains 
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have mutations within the 81-bp hot-spot region 
(codons 507 to 533) of the RNA polymerase β-subunit 
(rpoB) gene.
2
Over the last 15 years, Kapur et al. and 
Telenti et al. have identified the molecular basis of 
rifampin resistance in M. tuberculosis. Some researchs 
reported that almost 90 % of rifampicin resistant 
isolate are also resistant to isoniazid.  Therefore, 
resistance to rifampicin is  used to be a surrogate 
marker of  MDR-TB.
3,4 
 Lingala et al,2010 reported, for the first time 
multiple silent mutations, between the codons 145-
184 (outside the hot spot region). Present study aims 
to study amplify a 1700 bp fragment of rpoB gene of 
multidrug resistance M. tuberculosis (MDR-TB) isolate 
and determine types of mutation beyond the core 
region.
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MATERIALS AND METHODS 
Materials 
Mycobacterium strains of MDR-TB 885 was 
obtained from culture collection of Regional Health 
Laboratory, Surabaya, East Java, rifampicin 4 ppm, 
Lowenstein-Jenssen medium (L-J medium), Miniprep 
DNA isolation kit (Invitrogen) 
 
Methods  
Subculture on L-J medium: A loopful of isolate 
MDR-TB was inoculated on L-J media with 4 ppm 
rifampicin and incubated at 370 C for 21 days. 
DNA extraction: A loopful of  MDR-TB growth on 
L-J medium, was added to NaCl 0.9%. and lysed by 
TE(Tris-EDTA) 1X, lysis cell solution (guanidin 
thiocyanate, Tris-HCl, EDTA and Triton-X) and 20 μl 
ddH2O.  The mixture solutions was shaked for 10 
minutes and centrifuged at 100 rpm for 2 minutes. 
Genomic DNA  was extracted by modified Boom 
methods using buffer solution,  70% ethanol, acetone, 
and TE as described previously. DNA concentration 
yields was detected by nanogram.
6 
Amplification and Sequencing 1700 bp fragment: 
Amplification of fragment rpoB gene was carried out 
using primers FNdeR1 5’-GCC ATA TGA TGT CTC CGA 
TCG ACC ACT TC 3’ and RBamR1 5’ GTG GAT CCT GTC 
GTG CAT CAC AGT GAT GTA G 3’. Total volume of PCR 
were 20 μL Amplification conditions was set on 
described steps : a cycle of preheating at 95°C for 15 
minutes, amplifying in 45 cycles (1 minute at 94°C, 1 
minute at 58°C,  1 minute 72°C) and post extension for 
5 minutes at 72°C. Amplification product of 1700 bp 
was visualized on 1,5 % agarose. Sequencing was done 
at First Base Laboratory, Singapore using specific 
primers as described previously.  
DNA sequence analysis: DNA sequences were 
analyzed after DNA sequencing by BLAST using 
multiple sequence alignments (http://www.ncbi. 
nlm.nih.gov/BLAST) and MEGA4. Mutations were 
detected in the respective gene by comparison with 
M. tuberculosis H37Rv (wild-type reference laboratory 
strain). 
 
RESULTS 
During PCR condition was optimized, based on 
advice given from the program Clone Manager 6 and 
adapted to the tool. The purpose of PCR was to 
amplify the rpoB gene. The result of PCR consisted of 
PCR product of + 1.7 kb that were detectable trough 
electrophoresis as presented in Figure 1.  
 
Figure1. Electroforegram of PCR Product on 1,5% 
agarose 
 
1. H37Rv isolate; 2. Biomolecular lab.MDR-TB 
isolate; 3. 836 isolate; 4. 885 isolate, 5. Ladder gene 
marker HindIII / λ; The target rpoB gene fragment of 
1707 bp. 
 
Nucleotide sequencing results were analyzed 
using the program MEGA 4. Sequence alignment of 
the sample PCR product and a few sequences of MDR-
TB in some countries around the world that are 
available in data base (www.ncbi.nlm.nih.gov) were 
performed at the nucleotide codons 585-732. The 
results showed some differences with the alignment 
of nucleotide sequences of wild type M. tuberculosis 
H37Rv as listed in Table 1. 
 
 
 
The result of sequence analysis showed that 
there were mutations such as S594A, S626V, T629A. 
All detected mutations were beyond the core region 
of rpoB gene, i.e. in downstream of the core region. 
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 Comparison with some of the sequences of 
several MDR-TB countries formed a phylogeny tree as 
can be seen in Figure 2. 
 
 
Figure 2 
The 885 isolate 
 
 
DISCUSSION 
Culture remains the most sensitive and reliable 
methods for detection of M. tuberculosis drug 
resistance. However, phenotypic testing is time-
consuming and requires specialized laboratory 
facilities. Therefore, there is a need for rapid 
molecular methods for detection of drug resistance. 
This study illustrates that molecular methods for 
antimicrobial susceptibility testing of MDR M. 
tuberculosis isolates test not only primary mutational 
hot-spot regions of the rpoB.  
The analysis in this study revealed several amino acid 
differences. In the 885 isolates there is a change from 
the wild type as follows S594A, S626V, T629A. Amino 
acid changes did not occur in the hot spot region (81 
bp, codons 507-533). During 90-98% of rifampin-
resistant M. tuberculosis were reported to have 
mutations in the core area. However, there is also a 
low level of resistance was reported that showed 
mutations outside the region, namely the L176F.
7
 
Multiple silent mutations in codon regions 145 to 148 
rpoB gene of MDR-TB were also found in studies in 
India.
4
 
 In the 885 isolate, the first mutation is S594A, 
from serine to alanine which is polar to non polar, 
with changes in the first two nucleotides of the codon. 
The next change is the S626V, serine to valine which is 
non polar, because changes in the third nucleotide of 
the codons. Other changes are T629A, which are polar 
threonine to alanine which is polar, due to changes in 
the first two nucleotides of the codon. Serine and 
threonine are polar amino acids with side chains are 
reactive. Serine is containing oxygen atoms which act 
as potent nucleophiles in several enzymes. Threonine 
is containing hydroxyl groups which contribute to the 
formation of hydrogen bonds.
8 
Generally stated that the resistance to rifampicin 
is due to mutations in the rpoB core region. Mutations 
in these regions produce a high level resistance (MIC> 
32μg/ml). In this study, the concentration of 
rifampicin were added to the culture medium for 
optimal growth is 4 ppm and found mutations outside 
the core area. It is similar to the studies that have 
been done, that mutations outside the region usually 
associated with low-level resistance (MIC, 4 μg / ml).
9
 
Thus it can be said that isolates used in this study were 
MDR-TB isolates with low resistance levels. 
The tree of phylogeny indicated that isolates 885 
closer to the MDR isolates from Belarus and Iran with 
the time difference of less than 5 years (Mega 4). This 
isolate included in the Beijing family group which is 
spread widely around the world.
10 
It is due to M. 
tuberculosis is a travel disease as HIV. 
 
CONCLUSION 
Some mutations were showed in this study, i.e  
T629A,S626V,D623P, and Q624K. This region of 
mutation is reported  for the first time, new mutations 
at downstream region of the core region of rpoB. 
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